CD79A and non-small cell lung carcinoma: Although the exact mechanism by which PCs and their antibodies in TLS contribute to cancer inhibition is not fully comprehended, a notable presence of B cells and PCs capable of producing IgG and IgA in TLS associated with ovarian cancer, melanoma, lung adenocarcinoma (LUAD), and NSCLC has been observed and found to be beneficial in improving the overall survival (OS) of patients [64–67].